---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-107632"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:45:28.788842+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings Q1 FY2025 net loss $9.0M; Cyclo merger on track

## Summary
- Net loss attributable to Rafael Holdings of $9.0M ($0.37 per share) vs $3.6M loss a year ago.
- Cash, cash equivalents and marketable securities of $54.3M as of October 31, 2024.
- Pending merger with Cyclo Therapeutics (CYTH) expected to close in Q1 2025 after shareholder vote.
- Cyclo Therapeutics' Phase 3 study for Trappsol Cyclo fully enrolled; interim results mid-2025.
- R&D expenses $1.3M (up from $0.5M) on consolidation of Cornerstone and Day Three.

## SEC filing metadata
- accession: 0001213900-24-107632
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390024107632/0001213900-24-107632-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390024107632/ea0224341-8k_rafael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-107632
- JSON: https://secwatch.observer/filing/0001213900-24-107632.json
- Plain text: https://secwatch.observer/filing/0001213900-24-107632.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.